SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 893.64 |
| Enterprise Value ($M) | 907.19 |
| Book Value ($M) | 314.66 |
| Book Value / Share | 2.85 |
| Price / Book | 2.84 |
| NCAV ($M) | 272.17 |
| NCAV / Share | 2.46 |
| Price / NCAV | 3.28 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.73 |
| Return on Assets (ROA) | -0.77 |
| Return on Equity (ROE) | -0.94 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 6.44 |
| Current Ratio | 6.44 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 341.53 |
| Assets | 384.02 |
| Liabilities | 69.36 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Point72 Asset Management, L.P. | |||
| 13G | Paradigm Biocapital Advisors LP | |||
| 13G/A | Fmr Llc | |||
| 13G/A | Venrock Healthcare Capital Partners II, L.P. | 9.99 | 27.41 | |
| 13G/A | Commodore Capital Lp | 9.30 | 70.09 | |
| 13G/A | Kynam Capital Management, LP | 8.36 | 57.82 | |
| 13G/A | Suvretta Capital Management, Llc | 0.00 | -100.00 | |
| 13D/A | Fairmount Funds Management LLC | 9.90 | 13.45 | |
| 13G/A | Ra Capital Management, L.p. | 0.00 | -100.00 | |
| 13G | Vanguard Group Inc | 5.27 | ||
| 13G/A | TCG Crossover GP I, LLC | 6.50 | 55.08 | |
| 13G/A | BlackRock, Inc. | 7.80 | 36.57 | |
| 13G/A | State Street Corp | 4.82 | -2.60 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 252,171 | 732,579 | 34.42 | |
| 129,347 | 514,229 | 25.15 | |
| 111,119 | 440,490 | 25.23 | |
| 151,483 | 671,404 | 22.56 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CGC – Canopy Growth Corporation | CGEM – Cullinan Therapeutics, Inc. |
| CGON – CG Oncology, Inc. | COLL – Collegium Pharmaceutical, Inc. |
| CPIX – Cumberland Pharmaceuticals Inc. |
Financial data and stock pages provided by
Fintel.io